BioCardia, Inc. - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
BCDA Nasdaq 3850 www.biocardia.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioCardia, Inc.

BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System - Jun 25th, 2025 6:00 am
BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 - May 21st, 2025 6:30 am
BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ... - May 15th, 2025 1:16 am
BioCardia Reports First Quarter 2025 Business Highlights and Financial Results - May 14th, 2025 2:05 pm
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 - May 9th, 2025 2:28 pm
BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study - May 6th, 2025 6:00 am
First subject enrolled in BioCardia’s Phase III heart failure therapy trial - May 2nd, 2025 9:03 am
Biotech Alert: Searches spiking for these stocks today - May 1st, 2025 10:15 am
BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company’s Lead Cell Therapy for Treatment of Heart Failure - May 1st, 2025 7:00 am
DSMB recommends continuation of BioCardia’s cell therapy trial for heart failure - Apr 16th, 2025 3:45 am
BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial - Apr 15th, 2025 6:30 am
Emory begins enrolment for BioCardia’s trial of ischemic heart failure therapy - Apr 14th, 2025 4:52 am
BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study - Apr 11th, 2025 7:15 am
BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ... - Apr 1st, 2025 1:03 am
ACC 25: Biocardia’s CardiAMP trial fails but cell therapy potential remains - Mar 31st, 2025 9:32 pm
BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today - Mar 31st, 2025 11:39 am
Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years - Mar 31st, 2025 6:00 am
BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Mar 28th, 2025 5:02 am
BioCardia Reports 2024 Business Highlights and Financial Results - Mar 26th, 2025 2:30 pm
BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 - Mar 21st, 2025 6:30 am